would it be fair to say, page-38

09/12/12 5:48:26 PM (View) Post Reply Back (+17)
Report Post Post OptionsPost New MessagePost ReplyAdd User to FavouritesAdd Stock to FavouritesEmail to a FriendIgnore MemberIgnore StockReport TOU Violation

Surges
Post #: 8869354
Price at time of posting: 1.7c
In Reply to msg: #8869334
IP: 124.149.xxx.xxx
Sentiment: ST Buy
Disclosure: Stock Held
Views: 4385



full width | single post There are several scenarios for a " deal " possibility here.

My previous assumption to get partnering activities progressed to such a level that share price will be at multiples of current level and then raise money on the heels of such a development is still an option.

After all, we are still a spec company and rules apply.
I learned the hard way that as long as OBJ is not fully derisked, all possible outcomes need to be considered.


But if OBJ raises money to bring its own product into the market from a much increased share price level, market will not necessarily view this as a negative.
Sentiment would be lifted to such a degree that a CR would not dampen it considerably, outlook to partnership deals would be very alive and expected short term as well.




In this context, it would probably be worthwhile to analyse how far progressed our own programs are.
We can take from the latest update that we have 3 product programs of our own, some already at prototype status.

This would imply that management might not need or want to wait until license deals with partners are already signed, probably only until such an event is widely expected.



Money for our programs either comes from direct milestone payments from our partners or is raised by CRs or, alternatively, provided by CSIs.

The latest option is something OBJ might be well eligible for, something out of its grasp until now.

The possibility of a CSI from the US is something I suspected ever since the update from P&G last week and the revelation of Pfizer's involvement.
These companies are so massive that a certain ownership from their side is simply to be expected.
OBJ management would be indeed extremely successful to avoid a T/O in the future.
A CSI might well be the compromise and would provide funds for our own products to market.



Another option is the long lost UK FMCG.
I expect surprise news from them at any given time.
They went silent after consumer studies over a year ago.
This is extremely suspicious given the fact that P&G is moving forward so swiftly ( in biotech terms ) within similar market segments.
The UK FMCG had progressed for an OTC product within the healthcare division.



GSK could come forward and give us a concrete outlook of what to expect from the oral health products they are developing.
Any such update would push price up as well, particularly when timelines are shared as in P&G's disclosure of clinical study starting date early next year.


All this should/ can eventuate prior to the option expiry date.
My personal opinion is that our own products will provide the trigger for the associated milestone requirement.


These developments should take shape early next year.
A lot to look forward to.





Nice Post Surges, is it still early this year?